Pub Date : 2026-01-04DOI: 10.3390/antibiotics15010054
Simon J L Teskey, Lisa Khoma, Michelle Lorbes, Chris C Miller
Topical antibiotics have long been used for the prevention and treatment of superficial skin and soft tissue infections; however, increasing evidence indicates that their clinical value is undermined by rising antimicrobial resistance, high rates of allergic sensitization, inadequate activity against biofilms, and a lack of wound-healing properties. Agents such as bacitracin, neomycin, polymyxin B, mupirocin, and fusidic acid act through narrow, target-specific mechanisms that facilitate resistance selection and provide limited benefit in chronic or polymicrobial wound environments. Contemporary antimicrobial stewardship frameworks therefore discourage routine use of topical antibiotics and increasingly favor non-antibiotic antiseptics with broad-spectrum activity and low resistance risk, including silver, iodine, polyhexamethylene biguanide, octenidine, and medical-grade honey. These modalities, however, primarily serve to reduce microbial burden and do not directly address the underlying biological impairments that prevent healing. Nitric oxide-releasing gels (NORGs) represent a novel class of topical antimicrobials that combine multi-target bactericidal activity with physiologic pro-healing effects. Nitric oxide exerts potent antimicrobial and antibiofilm effects via oxidative and nitrosative stress, disruption of metabolic pathways, inhibition of DNA replication, and interference with quorum sensing. Simultaneously, nitric oxide enhances angiogenesis, modulates inflammation, improves microvascular perfusion, and promotes fibroblast and keratinocyte function. Preclinical models and early-phase clinical studies demonstrate broad-spectrum efficacy-including activity against multidrug-resistant organisms-with favorable tolerability and minimal risk of resistance development. Although the current evidence base remains preliminary, NORGs offer a promising antimicrobial platform with the potential to reduce reliance on topical antibiotics while simultaneously addressing key barriers to wound healing. Larger randomized controlled trials, direct comparisons with established advanced dressings, and robust pharmacoeconomic evaluations are needed to define their optimal role within stewardship-aligned wound-care practice.
{"title":"Nitric Oxide-Releasing Gels in the Context of Antimicrobial Stewardship, Biofilm Management, and Wound-Repair Biology.","authors":"Simon J L Teskey, Lisa Khoma, Michelle Lorbes, Chris C Miller","doi":"10.3390/antibiotics15010054","DOIUrl":"10.3390/antibiotics15010054","url":null,"abstract":"<p><p>Topical antibiotics have long been used for the prevention and treatment of superficial skin and soft tissue infections; however, increasing evidence indicates that their clinical value is undermined by rising antimicrobial resistance, high rates of allergic sensitization, inadequate activity against biofilms, and a lack of wound-healing properties. Agents such as bacitracin, neomycin, polymyxin B, mupirocin, and fusidic acid act through narrow, target-specific mechanisms that facilitate resistance selection and provide limited benefit in chronic or polymicrobial wound environments. Contemporary antimicrobial stewardship frameworks therefore discourage routine use of topical antibiotics and increasingly favor non-antibiotic antiseptics with broad-spectrum activity and low resistance risk, including silver, iodine, polyhexamethylene biguanide, octenidine, and medical-grade honey. These modalities, however, primarily serve to reduce microbial burden and do not directly address the underlying biological impairments that prevent healing. Nitric oxide-releasing gels (NORGs) represent a novel class of topical antimicrobials that combine multi-target bactericidal activity with physiologic pro-healing effects. Nitric oxide exerts potent antimicrobial and antibiofilm effects via oxidative and nitrosative stress, disruption of metabolic pathways, inhibition of DNA replication, and interference with quorum sensing. Simultaneously, nitric oxide enhances angiogenesis, modulates inflammation, improves microvascular perfusion, and promotes fibroblast and keratinocyte function. Preclinical models and early-phase clinical studies demonstrate broad-spectrum efficacy-including activity against multidrug-resistant organisms-with favorable tolerability and minimal risk of resistance development. Although the current evidence base remains preliminary, NORGs offer a promising antimicrobial platform with the potential to reduce reliance on topical antibiotics while simultaneously addressing key barriers to wound healing. Larger randomized controlled trials, direct comparisons with established advanced dressings, and robust pharmacoeconomic evaluations are needed to define their optimal role within stewardship-aligned wound-care practice.</p>","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"15 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12838158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146068451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: This study aimed to clarify the area under the curve (AUC) for obtaining better clinical outcomes and to demonstrate vancomycin dosing for achieving the AUC in haemodialysis (HD). Methods: The vancomycin concentration was measured before the second HD. The AUC24-48h after the initial HD was assessed to evaluate its correlation with an early clinical response and to determine the dosing regimen, assuming an inter-dialysis interval of 48 h, even if the interval was 72 h. Results: An AUC/MIC ≥ 400 was an independent factor for an early response in treating MRSA infections and infections caused by methicillin-resistant Gram-positive organisms. An AUC of 600-700 μg·h/mL did not increase the incidence of adverse effects compared with that of <600 μg·h/mL. An AUC of 400-700 μg·h/mL was obtained in 90.5% of patients with a loading dose of 30 mg/kg followed by a maintenance dose of 10 mg/kg. Pre-dialysis concentrations were significantly higher than the trough concentration required in non-HD patients to achieve the same AUC category, and AUC24-48h was strongly correlated with pre-dialysis concentrations (R2 = 0.921). In a receiver operating characteristic curve, the cut-off value for an early response was 16.8 μg/mL for the pre-dialysis concentration/MIC. Conclusions: AUC24-48h after the initial HD/MIC of ≥400 μg/mL improves the clinical outcomes in patients on HD, and the target PK/PD can be achieved with an upper range of the recommended dose. The pre-dialysis concentration may be a reliable surrogate for the AUC, and the vancomycin dose could be adjusted according to this PK target.
{"title":"Vancomycin Dosing Regimen to Obtain the Target Area Under the Concentration-Time Curve, Which Provides an Early Treatment Response for Patients on Haemodialysis.","authors":"Minori Kambe, Takashi Ueda, Kazutaka Oda, Kazuhiro Sugiyama, Kazuhiko Nakajima, Naruhito Otani, Motoi Uchino, Yuki Horio, Ryuichi Kuwahara, Masanobu Toyama, Makoto Tomita, Atsuki Ide, Mayuko Ao, Yasuhiro Nozaki, Yoshio Takesue","doi":"10.3390/antibiotics15010047","DOIUrl":"10.3390/antibiotics15010047","url":null,"abstract":"<p><p><b>Objectives</b>: This study aimed to clarify the area under the curve (AUC) for obtaining better clinical outcomes and to demonstrate vancomycin dosing for achieving the AUC in haemodialysis (HD). <b>Methods</b>: The vancomycin concentration was measured before the second HD. The AUC<sub>24-48h</sub> after the initial HD was assessed to evaluate its correlation with an early clinical response and to determine the dosing regimen, assuming an inter-dialysis interval of 48 h, even if the interval was 72 h. <b>Results</b>: An AUC/MIC ≥ 400 was an independent factor for an early response in treating MRSA infections and infections caused by methicillin-resistant Gram-positive organisms. An AUC of 600-700 μg·h/mL did not increase the incidence of adverse effects compared with that of <600 μg·h/mL. An AUC of 400-700 μg·h/mL was obtained in 90.5% of patients with a loading dose of 30 mg/kg followed by a maintenance dose of 10 mg/kg. Pre-dialysis concentrations were significantly higher than the trough concentration required in non-HD patients to achieve the same AUC category, and AUC<sub>24-48h</sub> was strongly correlated with pre-dialysis concentrations (R<sup>2</sup> = 0.921). In a receiver operating characteristic curve, the cut-off value for an early response was 16.8 μg/mL for the pre-dialysis concentration/MIC. <b>Conclusions</b>: AUC<sub>24-48h</sub> after the initial HD/MIC of ≥400 μg/mL improves the clinical outcomes in patients on HD, and the target PK/PD can be achieved with an upper range of the recommended dose. The pre-dialysis concentration may be a reliable surrogate for the AUC, and the vancomycin dose could be adjusted according to this PK target.</p>","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"15 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12838393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146068639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-03DOI: 10.3390/antibiotics15010048
Paula Irina Barata, Liana Maria Chicea, Irena Nedelea, Carmen Nicoleta Strauti, Diana Deleanu, Maria Daniela Moț, Coralia Cotoraci, Cristian Oancea
Background: Non-Hodgkin lymphoma (NHL) is a malignancy of the immune system that includes several subtypes, most commonly diffuse large B-cell lymphoma and follicular lymphoma. Its etiology is multifactorial, with risk factors such as immunosuppressive therapy, infections, chemical exposure, and advanced age. A key aspect is the bidirectional relationship between lymphoma and immunodeficiency, which increases susceptibility to recurrent infections and complicates disease management. Case presentation: One particularly challenging case during the COVID-19 pandemic involved a patient with a personal history of diffuse B-cell non-Hodgkin lymphoma, diagnosed 5 years earlier, who had undergone eight cycles of rituximab-based chemotherapy. The patient tested positive for SARS-CoV-2 for three consecutive months and experienced repeated urinary tract infections warranting more in-depth investigations. The uniqueness of this case lies in the rare association of non-Hodgkin lymphoma, suspected post-rituximab immunodeficiency, severe COVID-19 infection, and recurrent urinary tract infections, which complicated clinical management. Despite appropriate treatment for both respiratory and urinary infections, as well as eight cycles of chemotherapy, the patient's condition continued to deteriorate significantly, ultimately requiring intravenous immunoglobulin replacement therapy. Following the treatment, the patient presented a remarkable clinical improvement, with resolution of the signs and symptoms, and an absence of further recurrent infections. The patient remained clinically stable under regular immunoglobulin replacement therapy, with sustained infection control and improved quality of life. Conclusions: This case highlights the importance of assessing immune status in patients with a hematological malignancy, especially when recurrent infections persist.
{"title":"Recurrent Urinary Tract Infections in a Patient with Diffuse Large B-Cell Lymphoma and Severe COVID-19: A Single Case of Suspected Immunosuppression Where Antibacterial Therapy Was Not Enough.","authors":"Paula Irina Barata, Liana Maria Chicea, Irena Nedelea, Carmen Nicoleta Strauti, Diana Deleanu, Maria Daniela Moț, Coralia Cotoraci, Cristian Oancea","doi":"10.3390/antibiotics15010048","DOIUrl":"10.3390/antibiotics15010048","url":null,"abstract":"<p><p><b>Background:</b> Non-Hodgkin lymphoma (NHL) is a malignancy of the immune system that includes several subtypes, most commonly diffuse large B-cell lymphoma and follicular lymphoma. Its etiology is multifactorial, with risk factors such as immunosuppressive therapy, infections, chemical exposure, and advanced age. A key aspect is the bidirectional relationship between lymphoma and immunodeficiency, which increases susceptibility to recurrent infections and complicates disease management. <b>Case presentation:</b> One particularly challenging case during the COVID-19 pandemic involved a patient with a personal history of diffuse B-cell non-Hodgkin lymphoma, diagnosed 5 years earlier, who had undergone eight cycles of rituximab-based chemotherapy. The patient tested positive for SARS-CoV-2 for three consecutive months and experienced repeated urinary tract infections warranting more in-depth investigations. The uniqueness of this case lies in the rare association of non-Hodgkin lymphoma, suspected post-rituximab immunodeficiency, severe COVID-19 infection, and recurrent urinary tract infections, which complicated clinical management. Despite appropriate treatment for both respiratory and urinary infections, as well as eight cycles of chemotherapy, the patient's condition continued to deteriorate significantly, ultimately requiring intravenous immunoglobulin replacement therapy. Following the treatment, the patient presented a remarkable clinical improvement, with resolution of the signs and symptoms, and an absence of further recurrent infections. The patient remained clinically stable under regular immunoglobulin replacement therapy, with sustained infection control and improved quality of life. <b>Conclusions:</b> This case highlights the importance of assessing immune status in patients with a hematological malignancy, especially when recurrent infections persist.</p>","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"15 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12837306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146068566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-03DOI: 10.3390/antibiotics15010051
Julio David Soto-López, Omar Velásquez-González, Manuel A Barrios-Izás, Moncef Belhassen-García, Juan Luis Muñoz-Bellido, Pedro Fernández-Soto, Antonio Muro
Background/objectives: The mammalian microbiota constitutes a reservoir of antimicrobial resistance genes (ARGs), which can be shaped by environmental and anthropogenic factors. Although bat-associated bacteria have been reported to harbor diverse ARGs globally, the ecological and evolutionary determinants driving this diversity remain unclear.
Methods: To characterize ARG diversity in wildlife exposed to contrasting levels of human influence, we analyzed homologs of resistance mechanisms from the Comprehensive Antibiotic Resistance Database in shotgun metagenomes of bat guano. Samples were collected from a colony exposed to continuous anthropogenic activity in Spain (Salamanca) and from a wild, non-impacted bat community in China (Guangdong). Metagenomic analyses revealed marked differences in taxonomic and resistome composition between sites.
Results: Salamanca samples contained numerous hospital-associated genera (e.g., Mycobacterium, Staphylococcus, Corynebacterium), while Guangdong was dominated by Lactococcus, Aeromonas, and Stenotrophomonas. β-lactamases and MurA transferase homologs were the most abundant ARGs in both datasets, yet Salamanca exhibited higher richness and functional diversity (median Shannon index = 1.5; Simpson = 0.8) than Guangdong (Shannon = 1.1; Simpson = 0.66). Salamanca also showed enrichment of clinically relevant ARGs, including qacG, emrR, bacA, and acrB, conferring resistance to antibiotics critical for human medicine. In contrast, Guangdong exhibited a more restricted resistome dominated by β-lactamase and MurA homologs. Beta diversity analysis confirmed significant compositional differences between resistomes (PERMANOVA, R2 = 0.019, F = 1.33, p = 0.001), indicating ecological rather than stochastic structuring.
Conclusions: These findings suggest that anthropogenic exposure enhances the diversity and evenness of resistance mechanisms within bat-associated microbiomes, potentially increasing their role as reservoirs of antimicrobial resistance.
背景/目的:哺乳动物微生物群构成了抗菌素耐药基因(ARGs)的储存库,可受环境和人为因素的影响。尽管据报道,蝙蝠相关细菌在全球范围内携带多种ARGs,但驱动这种多样性的生态和进化决定因素尚不清楚。方法:为了描述暴露于不同人类影响水平下的野生动物ARG多样性,我们分析了蝙蝠鸟粪霰弹枪宏基因组中综合抗生素耐药性数据库中耐药机制的同源性。样本采集自西班牙(萨拉曼卡)一个暴露于持续人类活动的种群和中国(广东)一个未受影响的野生蝙蝠群落。宏基因组分析显示,不同位点之间的分类和抗性组组成存在显著差异。结果:萨拉曼卡省样本中含有大量的医院相关属(如分枝杆菌、葡萄球菌、棒状杆菌),而广东以乳球菌、气单胞菌和窄养单胞菌为主。β-内酰胺酶和MurA转移酶同源物是两个数据集中最丰富的ARGs,但萨拉曼卡的丰富度和功能多样性(Shannon指数中位数为1.5;Simpson = 0.8)高于广东(Shannon = 1.1; Simpson = 0.66)。Salamanca还显示了临床相关ARGs的富集,包括qacG、emrR、bacA和acrB,赋予对人类医学至关重要的抗生素耐药性。相比之下,广东的抗性组以β-内酰胺酶和MurA同源物为主。Beta多样性分析证实了抗性组的组成差异显著(PERMANOVA, R2 = 0.019, F = 1.33, p = 0.001),表明抗性组是生态结构而非随机结构。结论:这些发现表明,人为暴露增强了蝙蝠相关微生物组耐药机制的多样性和均匀性,潜在地增加了它们作为抗微生物药物耐药性储存库的作用。
{"title":"Metagenomic Comparison of Bat Colony Resistomes Across Anthropogenic and Pristine Habitats.","authors":"Julio David Soto-López, Omar Velásquez-González, Manuel A Barrios-Izás, Moncef Belhassen-García, Juan Luis Muñoz-Bellido, Pedro Fernández-Soto, Antonio Muro","doi":"10.3390/antibiotics15010051","DOIUrl":"10.3390/antibiotics15010051","url":null,"abstract":"<p><strong>Background/objectives: </strong>The mammalian microbiota constitutes a reservoir of antimicrobial resistance genes (ARGs), which can be shaped by environmental and anthropogenic factors. Although bat-associated bacteria have been reported to harbor diverse ARGs globally, the ecological and evolutionary determinants driving this diversity remain unclear.</p><p><strong>Methods: </strong>To characterize ARG diversity in wildlife exposed to contrasting levels of human influence, we analyzed homologs of resistance mechanisms from the Comprehensive Antibiotic Resistance Database in shotgun metagenomes of bat guano. Samples were collected from a colony exposed to continuous anthropogenic activity in Spain (Salamanca) and from a wild, non-impacted bat community in China (Guangdong). Metagenomic analyses revealed marked differences in taxonomic and resistome composition between sites.</p><p><strong>Results: </strong>Salamanca samples contained numerous hospital-associated genera (e.g., <i>Mycobacterium</i>, <i>Staphylococcus</i>, <i>Corynebacterium</i>), while Guangdong was dominated by <i>Lactococcus</i>, <i>Aeromonas</i>, and <i>Stenotrophomonas</i>. β-lactamases and MurA transferase homologs were the most abundant ARGs in both datasets, yet Salamanca exhibited higher richness and functional diversity (median Shannon index = 1.5; Simpson = 0.8) than Guangdong (Shannon = 1.1; Simpson = 0.66). Salamanca also showed enrichment of clinically relevant ARGs, including <i>qacG</i>, <i>emrR</i>, <i>bacA</i>, and <i>acrB</i>, conferring resistance to antibiotics critical for human medicine. In contrast, Guangdong exhibited a more restricted resistome dominated by β-lactamase and MurA homologs. Beta diversity analysis confirmed significant compositional differences between resistomes (PERMANOVA, R<sup>2</sup> = 0.019, F = 1.33, <i>p</i> = 0.001), indicating ecological rather than stochastic structuring.</p><p><strong>Conclusions: </strong>These findings suggest that anthropogenic exposure enhances the diversity and evenness of resistance mechanisms within bat-associated microbiomes, potentially increasing their role as reservoirs of antimicrobial resistance.</p>","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"15 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12838372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146068318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-03DOI: 10.3390/antibiotics15010046
Sara Barbarulo, Elisa Rampacci, Sara Primavilla, Valentina Stefanetti, Fabrizio Passamonti
Background: Wildlife is increasingly recognized as an important component in the epidemiology of zoonotic pathogens. Salmonella spp., a leading cause of foodborne disease worldwide, can circulate across human, domestic animal, and environmental interfaces. European hedgehogs (Erinaceus europaeus), a synanthropic species frequently inhabiting urban and peri-urban areas, may act as reservoirs or sentinels for Salmonella.
Objectives: The aim of this study was to investigate the prevalence, serotype distribution, and antimicrobial susceptibility profiles of Salmonella spp. isolated from European hedgehogs admitted to wildlife rehabilitation centers in Italy.
Methods: Fecal samples were collected from 100 European hedgehogs housed in five wildlife rehabilitation centers located in four Italian regions. Salmonella spp. were isolated using standard bacteriological methods, serotyped according to the Kaufmann-White-Le Minor scheme, and tested for antimicrobial susceptibility by broth microdilution for ampicillin, enrofloxacin, and sulfamethoxazole-trimethoprim. Minimum inhibitory concentrations (MICs) were interpreted following CLSI guidelines.
Results: Salmonella spp. was isolated from 30% of the animals sampled. Four serovars were identified, with S. Enteritidis (50%) and S. Typhimurium (36.7%) being the most prevalent, followed by S. Agona (10%) and S. Chester (3.3%). Antimicrobial susceptibility testing revealed a high level of susceptibility, with 90% of isolates sensitive to all tested antibiotics. One S. enteritidis strain showed resistance to enrofloxacin and sulfamethoxazole-trimethoprim, while two isolates exhibited intermediate susceptibility to enrofloxacin.
Conclusions: The detection of Salmonella serovars commonly associated with human infections in European hedgehogs highlights the potential role of this species in the ecology of zoonotic Salmonella. Although antimicrobial resistance levels were low, the presence of resistant and intermediate strains underscores the importance of continued surveillance. Despite some limitations related to the study design and sample representativeness, these results support the need for further large-scale investigations, reinforcing the need for integrated One Health surveillance strategies.
{"title":"Characterization of <i>Salmonella</i> spp. Isolates from European Hedgehogs (<i>Erinaceus europaeus</i>) in Italy: Serotypes and Antimicrobial Susceptibility Profiles.","authors":"Sara Barbarulo, Elisa Rampacci, Sara Primavilla, Valentina Stefanetti, Fabrizio Passamonti","doi":"10.3390/antibiotics15010046","DOIUrl":"10.3390/antibiotics15010046","url":null,"abstract":"<p><strong>Background: </strong>Wildlife is increasingly recognized as an important component in the epidemiology of zoonotic pathogens. <i>Salmonella</i> spp., a leading cause of foodborne disease worldwide, can circulate across human, domestic animal, and environmental interfaces. European hedgehogs (<i>Erinaceus europaeus</i>), a synanthropic species frequently inhabiting urban and peri-urban areas, may act as reservoirs or sentinels for <i>Salmonella</i>.</p><p><strong>Objectives: </strong>The aim of this study was to investigate the prevalence, serotype distribution, and antimicrobial susceptibility profiles of <i>Salmonella</i> spp. isolated from European hedgehogs admitted to wildlife rehabilitation centers in Italy.</p><p><strong>Methods: </strong>Fecal samples were collected from 100 European hedgehogs housed in five wildlife rehabilitation centers located in four Italian regions. <i>Salmonella</i> spp. were isolated using standard bacteriological methods, serotyped according to the Kaufmann-White-Le Minor scheme, and tested for antimicrobial susceptibility by broth microdilution for ampicillin, enrofloxacin, and sulfamethoxazole-trimethoprim. Minimum inhibitory concentrations (MICs) were interpreted following CLSI guidelines.</p><p><strong>Results: </strong><i>Salmonella</i> spp. was isolated from 30% of the animals sampled. Four serovars were identified, with <i>S.</i> Enteritidis (50%) and <i>S.</i> Typhimurium (36.7%) being the most prevalent, followed by <i>S.</i> Agona (10%) and <i>S.</i> Chester (3.3%). Antimicrobial susceptibility testing revealed a high level of susceptibility, with 90% of isolates sensitive to all tested antibiotics. One <i>S. enteritidis</i> strain showed resistance to enrofloxacin and sulfamethoxazole-trimethoprim, while two isolates exhibited intermediate susceptibility to enrofloxacin.</p><p><strong>Conclusions: </strong>The detection of <i>Salmonella</i> serovars commonly associated with human infections in European hedgehogs highlights the potential role of this species in the ecology of zoonotic <i>Salmonella</i>. Although antimicrobial resistance levels were low, the presence of resistant and intermediate strains underscores the importance of continued surveillance. Despite some limitations related to the study design and sample representativeness, these results support the need for further large-scale investigations, reinforcing the need for integrated One Health surveillance strategies.</p>","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"15 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12837997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146068277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Hospitals are recognized as point sources of antimicrobials in urban wastewater systems; however, comprehensive evaluations of their discharge profiles have not yet been conducted. Methods: This study presents a multi-site investigation of residual antimicrobial concentrations in effluents from five general hospitals and a commercial facility in the metropolitan area of Japan. Over a 12-week period (December 2023-March 2024), extensive sampling was conducted. Fifteen antimicrobials from multiple classes were quantified using high-throughput analysis. Results: The results revealed consistently higher concentrations in hospital effluents, particularly for levofloxacin, vancomycin, and ampicillin, than in non-clinical sites. Distinct facility-specific and temporal patterns suggest strong links between local prescribing practices and the effluent composition. Some compounds, such as clarithromycin and minocycline, showed dual contributions from both hospital and commercial sources. Conclusions: These findings highlight the need for source-targeted monitoring and antimicrobial pollution control strategies and provide a foundation for expanding surveillance efforts and informing environmental policies related to antimicrobial resistance (AMR).
{"title":"First Multi-Facility Antimicrobial Surveillance in Japanese Hospital Wastewater Reveals Spatiotemporal Trends and Source-Specific Environmental Loads.","authors":"Takashi Azuma, Ai Tsukada, Naoki Fujii, Miwa Katagiri, Itaru Nakamura, Hidefumi Shimizu, Keita Tatsuno, Manabu Watanabe, Norio Ohmagari, Nobuaki Matsunaga","doi":"10.3390/antibiotics15010050","DOIUrl":"10.3390/antibiotics15010050","url":null,"abstract":"<p><p><b>Background</b>: Hospitals are recognized as point sources of antimicrobials in urban wastewater systems; however, comprehensive evaluations of their discharge profiles have not yet been conducted. <b>Methods</b>: This study presents a multi-site investigation of residual antimicrobial concentrations in effluents from five general hospitals and a commercial facility in the metropolitan area of Japan. Over a 12-week period (December 2023-March 2024), extensive sampling was conducted. Fifteen antimicrobials from multiple classes were quantified using high-throughput analysis. <b>Results</b>: The results revealed consistently higher concentrations in hospital effluents, particularly for levofloxacin, vancomycin, and ampicillin, than in non-clinical sites. Distinct facility-specific and temporal patterns suggest strong links between local prescribing practices and the effluent composition. Some compounds, such as clarithromycin and minocycline, showed dual contributions from both hospital and commercial sources. <b>Conclusions</b>: These findings highlight the need for source-targeted monitoring and antimicrobial pollution control strategies and provide a foundation for expanding surveillance efforts and informing environmental policies related to antimicrobial resistance (AMR).</p>","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"15 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12837197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146068617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-03DOI: 10.3390/antibiotics15010049
Josef Yayan, Kurt Rasche
Background: Early administration of antibiotics is commonly recommended for pneumonia in intensive care unit (ICU) patients. However, the clinical benefit of very early empirical treatment remains uncertain and may reflect differences in illness severity, baseline risk, or care pathways, particularly in non-septic or hemodynamically stable ICU populations. Methods: We performed a retrospective cohort study using the Medical Information Mart for Intensive Care IV (v2.2) database to evaluate the observational association between antibiotic timing and in-hospital mortality among adult ICU patients with pneumonia. Patients were categorized as receiving early (<3 h) or delayed (≥3 h) antibiotic therapy after ICU admission. A multivariable logistic regression model adjusted only for age and sex. Given the absence of detailed severity-of-illness measures, no causal inference was intended, and all analyses were considered hypothesis-generating. Additional analyses exploring antibiotic class, dosing frequency, and combination therapy were conducted in an exploratory manner, given substantial variation in sample sizes and a high risk of confounding by indication, misclassification, immortal-time, and survivorship bias. Results: Among 7569 ICU patients with pneumonia, 56.5% received antibiotics within three hours of ICU admission. Early antibiotic initiation was associated with higher in-hospital mortality than delayed therapy (26.1% vs. 21.5%; OR 1.30, 95% CI 1.16-1.44; p < 0.001). Because validated severity-of-illness measures were unavailable, residual confounding and confounding by indication are likely and may largely explain this association. A potential signal of increased mortality was observed in patients receiving ≥3 doses of levofloxacin (OR 4.39, 95% CI 1.13-17.02); however, this subgroup was small and the finding is highly susceptible to survivorship and indication bias. Mortality appeared lower in patients receiving two or three antibiotics compared with monotherapy, but marked group imbalances, lack of restriction or stratification, and clinical selection effects limit interpretability. Regimens involving ≥4 agents were rare and primarily associated with prolonged ICU length of stay rather than a clear mortality difference. Conclusions: In this large retrospective ICU cohort, very early antibiotic administration for pneumonia was observationally associated with higher in-hospital mortality. Causality cannot be inferred, and early treatment likely represents a marker of higher baseline risk or clinical urgency rather than a harmful exposure. These findings challenge the assumption that earlier antibiotic initiation is uniformly beneficial and underscore the importance of individualized, stewardship-aligned, and context-dependent decision-making regarding antimicrobial timing and intensity in critically ill patients.
背景:重症监护病房(ICU)肺炎患者通常推荐早期使用抗生素。然而,早期经验性治疗的临床获益仍然不确定,可能反映了疾病严重程度、基线风险或护理途径的差异,特别是在非脓毒症或血流动力学稳定的ICU人群中。方法:我们使用重症监护医学信息市场IV (v2.2)数据库进行了一项回顾性队列研究,以评估ICU成人肺炎患者抗生素使用时间与住院死亡率之间的观察性关联。结果:7569例ICU肺炎患者中,56.5%的患者在入院后3小时内接受了抗生素治疗。早期使用抗生素与延迟治疗相比,住院死亡率更高(26.1%对21.5%;OR 1.30, 95% CI 1.16-1.44; p < 0.001)。由于无法获得有效的疾病严重程度测量,残留混淆和指征混淆很可能在很大程度上解释了这种关联。在接受≥3剂量左氧氟沙星治疗的患者中观察到死亡率增加的潜在信号(OR 4.39, 95% CI 1.13-17.02);然而,这个亚组很小,而且研究结果很容易受到生存和指征偏倚的影响。与单药治疗相比,接受两种或三种抗生素治疗的患者死亡率较低,但明显的组失衡,缺乏限制或分层,临床选择效应限制了可解释性。涉及≥4种药物的方案很少,主要与延长ICU住院时间有关,而不是明显的死亡率差异。结论:在这个大型回顾性ICU队列中,观察到肺炎的早期抗生素治疗与较高的住院死亡率相关。因果关系无法推断,早期治疗可能代表较高的基线风险或临床紧迫性,而不是有害暴露。这些发现挑战了早期开始使用抗生素一致有益的假设,并强调了危重患者在抗菌时间和强度方面个性化、管理一致和情境依赖决策的重要性。
{"title":"Timing of Antibiotics in ICU Pneumonia: An Observational Association Between Early Treatment and Higher Mortality.","authors":"Josef Yayan, Kurt Rasche","doi":"10.3390/antibiotics15010049","DOIUrl":"10.3390/antibiotics15010049","url":null,"abstract":"<p><p><b>Background:</b> Early administration of antibiotics is commonly recommended for pneumonia in intensive care unit (ICU) patients. However, the clinical benefit of very early empirical treatment remains uncertain and may reflect differences in illness severity, baseline risk, or care pathways, particularly in non-septic or hemodynamically stable ICU populations. <b>Methods:</b> We performed a retrospective cohort study using the Medical Information Mart for Intensive Care IV (v2.2) database to evaluate the observational association between antibiotic timing and in-hospital mortality among adult ICU patients with pneumonia. Patients were categorized as receiving early (<3 h) or delayed (≥3 h) antibiotic therapy after ICU admission. A multivariable logistic regression model adjusted only for age and sex. Given the absence of detailed severity-of-illness measures, no causal inference was intended, and all analyses were considered hypothesis-generating. Additional analyses exploring antibiotic class, dosing frequency, and combination therapy were conducted in an exploratory manner, given substantial variation in sample sizes and a high risk of confounding by indication, misclassification, immortal-time, and survivorship bias. <b>Results:</b> Among 7569 ICU patients with pneumonia, 56.5% received antibiotics within three hours of ICU admission. Early antibiotic initiation was associated with higher in-hospital mortality than delayed therapy (26.1% vs. 21.5%; OR 1.30, 95% CI 1.16-1.44; <i>p</i> < 0.001). Because validated severity-of-illness measures were unavailable, residual confounding and confounding by indication are likely and may largely explain this association. A potential signal of increased mortality was observed in patients receiving ≥3 doses of levofloxacin (OR 4.39, 95% CI 1.13-17.02); however, this subgroup was small and the finding is highly susceptible to survivorship and indication bias. Mortality appeared lower in patients receiving two or three antibiotics compared with monotherapy, but marked group imbalances, lack of restriction or stratification, and clinical selection effects limit interpretability. Regimens involving ≥4 agents were rare and primarily associated with prolonged ICU length of stay rather than a clear mortality difference. <b>Conclusions:</b> In this large retrospective ICU cohort, very early antibiotic administration for pneumonia was observationally associated with higher in-hospital mortality. Causality cannot be inferred, and early treatment likely represents a marker of higher baseline risk or clinical urgency rather than a harmful exposure. These findings challenge the assumption that earlier antibiotic initiation is uniformly beneficial and underscore the importance of individualized, stewardship-aligned, and context-dependent decision-making regarding antimicrobial timing and intensity in critically ill patients.</p>","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"15 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12837492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146068648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.3390/antibiotics15010045
Mark J M Sullman, Timo J Lajunen
Background: Antimicrobial resistance (AMR) is a major global health threat, and Cyprus reports one of the highest levels of community antibiotic consumption in the EU. Despite their central role in antibiotic access and counselling, the stewardship practices and perspectives of community pharmacists in this regulated setting are not well documented. Methods: We conducted semi-structured qualitative interviews with 20 community pharmacists to explore their perspectives on antibiotic use and AMR. Results: We analysed the data using reflexive thematic analysis, revealing five key themes: regulation and control of dispensing; pharmacist-patient interaction and misuse; antimicrobial stewardship and public education; safety and professional responsibility; and systemic barriers. Pharmacists reported strict adherence to prescription-only rules, and described regulation and e-prescribing as a practical 'shield' that legitimised refusals and redirected some misuse from overt non-prescription requests towards attempts to reuse, extend, or 'top up' prior prescriptions and household leftovers. They described managing frequent patient demands for antibiotics for self-limiting conditions and using brief counselling scripts, written aids, and symptomatic alternatives to promote appropriate use. Participants emphasised the risks of antibiotic-related harms, including AMR and other health consequences, while also highlighting workload, access constraints, and communication difficulties as barriers to effective counselling. Overall, the findings indicate that community pharmacists in Cyprus function as front-line antimicrobial stewards. Conclusions: These accounts position community pharmacists in Cyprus as front-line antimicrobial stewards. Policy should consider supporting this function by providing enhanced communication tools, improving access pathways for timely prescriber review (including outside routine hours), and strengthening links between community pharmacy and national AMR action plans.
{"title":"Community Pharmacists' Perspectives on Antibiotic Misuse and Antimicrobial Resistance in Cyprus: A Reflexive Thematic Analysis.","authors":"Mark J M Sullman, Timo J Lajunen","doi":"10.3390/antibiotics15010045","DOIUrl":"10.3390/antibiotics15010045","url":null,"abstract":"<p><p><b>Background:</b> Antimicrobial resistance (AMR) is a major global health threat, and Cyprus reports one of the highest levels of community antibiotic consumption in the EU. Despite their central role in antibiotic access and counselling, the stewardship practices and perspectives of community pharmacists in this regulated setting are not well documented. <b>Methods:</b> We conducted semi-structured qualitative interviews with 20 community pharmacists to explore their perspectives on antibiotic use and AMR. <b>Results:</b> We analysed the data using reflexive thematic analysis, revealing five key themes: regulation and control of dispensing; pharmacist-patient interaction and misuse; antimicrobial stewardship and public education; safety and professional responsibility; and systemic barriers. Pharmacists reported strict adherence to prescription-only rules, and described regulation and e-prescribing as a practical 'shield' that legitimised refusals and redirected some misuse from overt non-prescription requests towards attempts to reuse, extend, or 'top up' prior prescriptions and household leftovers. They described managing frequent patient demands for antibiotics for self-limiting conditions and using brief counselling scripts, written aids, and symptomatic alternatives to promote appropriate use. Participants emphasised the risks of antibiotic-related harms, including AMR and other health consequences, while also highlighting workload, access constraints, and communication difficulties as barriers to effective counselling. Overall, the findings indicate that community pharmacists in Cyprus function as front-line antimicrobial stewards. <b>Conclusions:</b> These accounts position community pharmacists in Cyprus as front-line antimicrobial stewards. Policy should consider supporting this function by providing enhanced communication tools, improving access pathways for timely prescriber review (including outside routine hours), and strengthening links between community pharmacy and national AMR action plans.</p>","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"15 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12837482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146068523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.3390/antibiotics15010044
Fatma A Mohamed, Mohamed Al-Bulushi, Szilvia Melegh, Bálint Timmer, Réka Meszéna, Csongor Freytag, Levente Laczkó, László Miló, Péter Urbán, Renáta Bőkényné-Tóth, Attila Gyenesei, Gábor Kardos, Adrienn Nyul, Edit Urbán, Tibor Pál, Ágnes Sonnevend
Background: Carbapenem-resistant Escherichia coli (CREC) producing OXA-48-like carbapenemase was first detected in Hungary in 2022. The aim of the present study was to characterize such strains isolated in 2022-2025 in Baranya County, Hungary. Methods: Antibiotic susceptibility and the whole-genome sequence (WGS) of E. coli isolates, identified as OXA-48-like carbapenemase producers using the CARBA-5 NG test, were established. The transferability of blaOXA-48-like plasmids was tested by conjugation. Results: Of the 6722 non-repeat E. coli isolates, 6 produced an OXA-48-like carbapenemase. They exhibited variable resistance to ertapenem and were susceptible to imipenem and meropenem. WGS revealed that all OXA-48-like producer E. coli belonged to high-risk clones: two clonally related OXA-181-producer E. coli ST405 were isolated in Hospital A, three OXA-244-producing E. coli ST38 (two identical via cgMLST from Hospital B), and an OXA-48-producing E. coli ST69. The blaOXA-48 and blaOXA-244 genes were chromosomally located, while blaOXA-181 was on a non-conjugative IncFIB-IncFIC plasmid. So far, the blaOXA-181-bearing plasmid of this incompatibility type has only been described in Ghana, but all blaOXA-48-like gene-carrying transposons in this study have already been identified in Europe and other continents. The E. coli ST38 isolates, showing close association based on core genome SNP distances to European and Qatari strains, belonged to Cluster A and harbored blaCTX-M-27. All but the E. coli ST69 isolate had cephalosporinase gene(s). Conclusions: This study describes small-scale intra-hospital transfers of OXA-48-like carbapenemase-producer E. coli. Interestingly, E. coli ST405 of Hungary carried blaOXA-181 on an IncFIB-IncFIC plasmid, which has only been reported from Africa so far.
{"title":"Emergence of OXA-48-like Carbapenemase-Producing <i>Escherichia coli</i> in Baranya County, Hungary.","authors":"Fatma A Mohamed, Mohamed Al-Bulushi, Szilvia Melegh, Bálint Timmer, Réka Meszéna, Csongor Freytag, Levente Laczkó, László Miló, Péter Urbán, Renáta Bőkényné-Tóth, Attila Gyenesei, Gábor Kardos, Adrienn Nyul, Edit Urbán, Tibor Pál, Ágnes Sonnevend","doi":"10.3390/antibiotics15010044","DOIUrl":"10.3390/antibiotics15010044","url":null,"abstract":"<p><p><b>Background</b>: Carbapenem-resistant <i>Escherichia coli</i> (CREC) producing OXA-48-like carbapenemase was first detected in Hungary in 2022. The aim of the present study was to characterize such strains isolated in 2022-2025 in Baranya County, Hungary. <b>Methods</b>: Antibiotic susceptibility and the whole-genome sequence (WGS) of <i>E. coli</i> isolates, identified as OXA-48-like carbapenemase producers using the CARBA-5 NG test, were established. The transferability of <i>bla</i><sub>OXA-48-like</sub> plasmids was tested by conjugation. <b>Results</b>: Of the 6722 non-repeat <i>E. coli</i> isolates, 6 produced an OXA-48-like carbapenemase. They exhibited variable resistance to ertapenem and were susceptible to imipenem and meropenem. WGS revealed that all OXA-48-like producer <i>E. coli</i> belonged to high-risk clones: two clonally related OXA-181-producer <i>E. coli</i> ST405 were isolated in Hospital A, three OXA-244-producing <i>E. coli</i> ST38 (two identical via cgMLST from Hospital B), and an OXA-48-producing <i>E. coli</i> ST69. The <i>bla</i><sub>OXA-48</sub> and <i>bla</i><sub>OXA-244</sub> genes were chromosomally located, while <i>bla</i><sub>OXA-181</sub> was on a non-conjugative IncFIB-IncFIC plasmid. So far, the <i>bla</i><sub>OXA-181</sub>-bearing plasmid of this incompatibility type has only been described in Ghana, but all <i>bla</i><sub>OXA-48-like</sub> gene-carrying transposons in this study have already been identified in Europe and other continents. The <i>E. coli</i> ST38 isolates, showing close association based on core genome SNP distances to European and Qatari strains, belonged to Cluster A and harbored <i>bla</i><sub>CTX-M-27.</sub> All but the <i>E. coli</i> ST69 isolate had cephalosporinase gene(s). <b>Conclusions</b>: This study describes small-scale intra-hospital transfers of OXA-48-like carbapenemase-producer <i>E. coli</i>. Interestingly, <i>E. coli</i> ST405 of Hungary carried <i>bla</i><sub>OXA-181</sub> on an IncFIB-IncFIC plasmid, which has only been reported from Africa so far.</p>","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"15 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12838234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146068557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.3390/antibiotics15010041
Vanessa Bassinello, Marcelo Fabiano Gomes Boriollo, Janaina Priscila Barbosa, Wagner Luís de Carvalho Bernardo, Mateus Cardoso Oliveira, Carlos Tadeu Dos Santos Dias, Cristina Paiva de Sousa
Background: This research aimed to investigate the antifungal and antibiofilm action of Lavandula angustifolia essential oil (LaEO) against certain Candida species and its toxicity on human keratinocytes. Methods: The minimum inhibitory concentration (MIC) and sessile minimum inhibitory concentration (SMIC) of LaEO were both determined by broth microdilution assays. The influence of LaEO treatment on the ultrastructural morphology of the biofilm and germ tubes was evaluated by scanning electron microscopy (SEM) and light microscopy. In vitro cytotoxicity studies were conducted using human HaCaT epidermal keratinocytes. Results: LaEO showed fungicidal action for all Candida species (125-4000 μg/mL). The SMIC>90 (C. albicans) ranged between 10,000 and 20,000 μg/mL and resulted in quantitative and qualitative cellular changes. LaEO also inhibited the developmental germ tube kinetics of C. albicans. The 50% cytotoxic concentration (CI50) for HaCaT cells was estimated at 420 μg/mL of LaEO, resulting in a selectivity index (SI) of 0.376 to 5.753 for planktonic cells and 0.056 to 0.321 for biofilm phases. Conclusions: LaEO was found to have antifungal action against Candida species and inhibited the pathogenic morphology of C. albicans. Its antibiofilm effects are comparable to the antifungal agent nystatin, and it can become an important component for the development of natural products applicable to alternative and complementary medicine and dentistry.
{"title":"<i>Lavandula angustifolia</i> Essential Oil as a Developmental Inhibitor of <i>Candida</i> Species and Biofilms.","authors":"Vanessa Bassinello, Marcelo Fabiano Gomes Boriollo, Janaina Priscila Barbosa, Wagner Luís de Carvalho Bernardo, Mateus Cardoso Oliveira, Carlos Tadeu Dos Santos Dias, Cristina Paiva de Sousa","doi":"10.3390/antibiotics15010041","DOIUrl":"10.3390/antibiotics15010041","url":null,"abstract":"<p><p><b>Background:</b> This research aimed to investigate the antifungal and antibiofilm action of <i>Lavandula angustifolia</i> essential oil (LaEO) against certain <i>Candida</i> species and its toxicity on human keratinocytes. <b>Methods:</b> The minimum inhibitory concentration (MIC) and sessile minimum inhibitory concentration (SMIC) of LaEO were both determined by broth microdilution assays. The influence of LaEO treatment on the ultrastructural morphology of the biofilm and germ tubes was evaluated by scanning electron microscopy (SEM) and light microscopy. In vitro cytotoxicity studies were conducted using human <i>HaCaT</i> epidermal keratinocytes. <b>Results:</b> LaEO showed fungicidal action for all <i>Candida</i> species (125-4000 μg/mL). The SMIC<sub>>90</sub> (<i>C. albicans</i>) ranged between 10,000 and 20,000 μg/mL and resulted in quantitative and qualitative cellular changes. LaEO also inhibited the developmental germ tube kinetics of <i>C. albicans</i>. The 50% cytotoxic concentration (CI<sub>50</sub>) for <i>HaCaT</i> cells was estimated at 420 μg/mL of LaEO, resulting in a selectivity index (SI) of 0.376 to 5.753 for planktonic cells and 0.056 to 0.321 for biofilm phases. <b>Conclusions:</b> LaEO was found to have antifungal action against <i>Candida</i> species and inhibited the pathogenic morphology of <i>C. albicans</i>. Its antibiofilm effects are comparable to the antifungal agent nystatin, and it can become an important component for the development of natural products applicable to alternative and complementary medicine and dentistry.</p>","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"15 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12837730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146068627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}